Matches in SemOpenAlex for { <https://semopenalex.org/work/W2274103071> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2274103071 endingPage "4516" @default.
- W2274103071 startingPage "4516" @default.
- W2274103071 abstract "4516 Background: High doses of calcitriol enhance the antitumor activity of multiple classes of chemotherapy in preclinical models and showed encouraging Phase 2 results in combination with docetaxel for AIPC. DN-101 is a new high-dose oral formulation designed to conveniently and reliably deliver the high calcitriol concentrations required for cancer therapy. Methods: Patients (pts) had metastatic AIPC, testosterone < 50 ng/ml, adequate organ function, clinical or PSA progression after anti-androgen withdrawal. Pts received weekly docetaxel 36 mg/m2 iv for 3 weeks of a 4-week cycle with standard dexamethasone and either 45 μg DN-101 or placebo orally 1 day prior to docetaxel. The study was powered at 85% to detect a 20% improvement in the fraction of patients with a ≥ 50% decline in serum PSA confirmed at least 4 weeks later (PSA response rate). Results: An interim analysis with a data cut-off of 6 months (June 2004) and median follow-up of 8 months is presented. 250 pts were randomized 1:1 at 48 sites in the US and Canada. Baseline characteristics were similar for both arms. PSA responses within 6 months (the primary endpoint) occurred more frequently in pts receiving DN-101 (58%) than placebo (49%), however this trend did not reach statistical significance (Cochran-Mantel-Haenszel chi square p=0.16). 102 patients had measurable disease. Objective response rate was 28% (3 CR, 10 PR of 46) vs. 20% (1 CR, 10 PR of 56) for DN-101 vs. placebo-treated patients. Most common grade 3/4 toxicities in the DN-101 and placebo-treated arms were neutropenia (8% vs. 8%), fatigue (7% vs. 15%), and hyperglycemia (6% vs. 11%). Serious adverse events occurred less frequently in DN-101 treated pts (24% vs. 36%, p=0.038). A similar trend was observed for AEs resulting in discontinuation of docetaxel (14% vs. 22% p=0.07). Conclusions: Early results show trends that favor DN-101 with respect to PSA and measurable tumor response rate and toxicity but do not reach statistical significance. Recommendations regarding further studies of DN-101 and docetaxel in AIPC will be made when the secondary endpoints of overall and progression-free survival are mature. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novacea Aventis, Novacea Aventis, Aventis Speakers Bureau, Novacea Novacea" @default.
- W2274103071 created "2016-06-24" @default.
- W2274103071 creator A5018844327 @default.
- W2274103071 creator A5019814247 @default.
- W2274103071 creator A5022466996 @default.
- W2274103071 creator A5032090669 @default.
- W2274103071 creator A5034837274 @default.
- W2274103071 creator A5050042851 @default.
- W2274103071 creator A5057439948 @default.
- W2274103071 creator A5078388888 @default.
- W2274103071 creator A5086830126 @default.
- W2274103071 creator A5090559402 @default.
- W2274103071 date "2005-06-01" @default.
- W2274103071 modified "2023-09-28" @default.
- W2274103071 title "Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC)" @default.
- W2274103071 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.4516" @default.
- W2274103071 hasPublicationYear "2005" @default.
- W2274103071 type Work @default.
- W2274103071 sameAs 2274103071 @default.
- W2274103071 citedByCount "32" @default.
- W2274103071 countsByYear W22741030712012 @default.
- W2274103071 countsByYear W22741030712014 @default.
- W2274103071 crossrefType "journal-article" @default.
- W2274103071 hasAuthorship W2274103071A5018844327 @default.
- W2274103071 hasAuthorship W2274103071A5019814247 @default.
- W2274103071 hasAuthorship W2274103071A5022466996 @default.
- W2274103071 hasAuthorship W2274103071A5032090669 @default.
- W2274103071 hasAuthorship W2274103071A5034837274 @default.
- W2274103071 hasAuthorship W2274103071A5050042851 @default.
- W2274103071 hasAuthorship W2274103071A5057439948 @default.
- W2274103071 hasAuthorship W2274103071A5078388888 @default.
- W2274103071 hasAuthorship W2274103071A5086830126 @default.
- W2274103071 hasAuthorship W2274103071A5090559402 @default.
- W2274103071 hasConcept C121608353 @default.
- W2274103071 hasConcept C124490489 @default.
- W2274103071 hasConcept C126322002 @default.
- W2274103071 hasConcept C126894567 @default.
- W2274103071 hasConcept C142724271 @default.
- W2274103071 hasConcept C143998085 @default.
- W2274103071 hasConcept C203092338 @default.
- W2274103071 hasConcept C204787440 @default.
- W2274103071 hasConcept C27081682 @default.
- W2274103071 hasConcept C2776079296 @default.
- W2274103071 hasConcept C2776694085 @default.
- W2274103071 hasConcept C2780192828 @default.
- W2274103071 hasConcept C2781190966 @default.
- W2274103071 hasConcept C535046627 @default.
- W2274103071 hasConcept C61943457 @default.
- W2274103071 hasConcept C65409693 @default.
- W2274103071 hasConcept C71924100 @default.
- W2274103071 hasConcept C90924648 @default.
- W2274103071 hasConceptScore W2274103071C121608353 @default.
- W2274103071 hasConceptScore W2274103071C124490489 @default.
- W2274103071 hasConceptScore W2274103071C126322002 @default.
- W2274103071 hasConceptScore W2274103071C126894567 @default.
- W2274103071 hasConceptScore W2274103071C142724271 @default.
- W2274103071 hasConceptScore W2274103071C143998085 @default.
- W2274103071 hasConceptScore W2274103071C203092338 @default.
- W2274103071 hasConceptScore W2274103071C204787440 @default.
- W2274103071 hasConceptScore W2274103071C27081682 @default.
- W2274103071 hasConceptScore W2274103071C2776079296 @default.
- W2274103071 hasConceptScore W2274103071C2776694085 @default.
- W2274103071 hasConceptScore W2274103071C2780192828 @default.
- W2274103071 hasConceptScore W2274103071C2781190966 @default.
- W2274103071 hasConceptScore W2274103071C535046627 @default.
- W2274103071 hasConceptScore W2274103071C61943457 @default.
- W2274103071 hasConceptScore W2274103071C65409693 @default.
- W2274103071 hasConceptScore W2274103071C71924100 @default.
- W2274103071 hasConceptScore W2274103071C90924648 @default.
- W2274103071 hasIssue "16_suppl" @default.
- W2274103071 hasLocation W22741030711 @default.
- W2274103071 hasOpenAccess W2274103071 @default.
- W2274103071 hasPrimaryLocation W22741030711 @default.
- W2274103071 hasRelatedWork W2010765098 @default.
- W2274103071 hasRelatedWork W2060708716 @default.
- W2274103071 hasRelatedWork W2094570582 @default.
- W2274103071 hasRelatedWork W2135620818 @default.
- W2274103071 hasRelatedWork W2407641156 @default.
- W2274103071 hasRelatedWork W2568045406 @default.
- W2274103071 hasRelatedWork W2588988563 @default.
- W2274103071 hasRelatedWork W2735900144 @default.
- W2274103071 hasRelatedWork W2770702948 @default.
- W2274103071 hasRelatedWork W2964624892 @default.
- W2274103071 hasVolume "23" @default.
- W2274103071 isParatext "false" @default.
- W2274103071 isRetracted "false" @default.
- W2274103071 magId "2274103071" @default.
- W2274103071 workType "article" @default.